CanSino Biologics released its latest financial report on September 30, 2024. The report shows that the company's total revenue reached 567,077,966.63 yuan, a growth of 222.88% compared to the same period last year, with a net profit of 263,646,520.16 yuan and a yearly growth rate of 76.09%. However, the company also reported an increase in total expenses, leading to a decrease in net profit compared to the previous year. Among the company's shareholders, HKSCC NOMINEES LIMITED holds the highest ownership percentage at 39.56%. The accuracy of the financial report was confirmed by director and CEO Xuefeng YU on October 29, 2024. CanSino Biologics' financial situation demonstrates strong revenue growth but also faces challenges in cost control.

CanSino Biologics released its latest financial report on September 30, 2024. The report shows that the company's total revenue reached 567,077,966.63 yuan, a growth of 222.88% compared to the same period last year, with a net profit of 263,646,520.16 yuan and a yearly growth rate of 76.09%. However, the company also reported an increase in total expenses, leading to a decrease in net profit compared to the previous year. Among the company's shareholders, HKSCC NOMINEES LIMITED holds the highest ownership percentage at 39.56%. The accuracy of the financial report was confirmed by director and CEO Xuefeng YU on October 29, 2024. CanSino Biologics' financial situation demonstrates strong revenue growth but also faces challenges in cost control.